Table II.
Clinical outcomes following oocyte vitrification-warming and embryo transfer in women with haematopoietic malignancies.
| Case | Type of malignancy* | Woman's age at oocyte cryopreservation | No. of oocytes vitrified | Woman's age at oocyte warming | Duration of stage (months) | No. of oocytes warmed | No. of survived oocytes | (%) | No. of oocytes fertilised | (%) | No. of utilised embryos developed (embryonic stage) | (%) | No. of embryo transfer cycles | No. of embryos transferred per cycle | Embryonic stage at transfer | Clinical pregnancy (gestational sac observation) | (%) | Live birth | (%) | Comment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CML | 23 | 13 | 30 | 87 | 13 | 9 | 69.2 | 9 | 100.0 | 4 (2: 5-cell, 1: 7-cell, 1: blastocyst) | 44.4 | 1 | 1 | 7-cell (fresh) | 0 | 0 | – | – | 3 surplus embryos were vitrified |
| 2 | NHL | 30 | 7 | 34 | 53 | 7 | 6 | 85.7 | 6 | 100.0 | 4 (3:4-cell, 1:blastocyst) | 66.7 | 4 | 1 | 4-cell (fresh) | 1 | 50 | 0 | 25 | – |
| 1 | Blastocyst (vitrified-warmed) | 1 | 1 | – | ||||||||||||||||
| 1 | 4-cell ( vitrified-warmed) | 0 | – | – | ||||||||||||||||
| 1 | 4-cell (vitrified-warmed) | 0 | – | – | ||||||||||||||||
| 3 | AA | 28 | 3 | 36 | 103 | 3 | 3 | 100.0 | 3 | 100.0 | 2(1: 8-cell, 1: blastocyst) | 66.7 | 1 | 1 | 8-cell (fresh) | 1 | 100 | 1 | 100 | 1 surplus embryos were vitrified |
| 4 | ALL | 36 | 3 | 41 | 67 | 3 | 1 | 33.3 | 1 | 100.0 | 0 | 0 | – | – | – | – | – | – | – | – |
| 5 | ALL | 30 | 9 | 35 | 62 | 9 | 8 | 88.9 | 7 | 87.5 | 2(1: 8-cell, 1: blastocyst) | 28.6 | 1 | 1 | 8-cell (fresh) | 1 | 100 | 1 | 100 | 1 surplus embryos were vitrified |
| 6 | AML | 30 | 7 | 34 | 52 | 7 | 7 | 100.0 | 7 | 100.0 | 2(1: 8-cell, 1: blastocyst) | 28.6 | 2 | 1 | 8-cell (fresh) | 0 | 50 | – | 50 | – |
| 1 | Blastocyst (vitrified-warmed) | 1 | 1 | – | ||||||||||||||||
| 7 | AML | 30 | 8 | 34 | 59 | 8 | 8 | 100.0 | 8 | 100.0 | 3(3: blastocysts) | 37.5 | 2 | 1 | Blastocyst (vitrified-warmed) | 0 | 50 | – | 50 | – |
| 1 | Blastocyst (vitrified-warmed) | 1 | 1 | – | ||||||||||||||||
| 8 | AML | 27 | 8 | 31 | 61 | 8 | 8 | 100.0 | 7 | 87.5 | 3(3: blastocysts) | 42.9 | 3 | 1 | Blastocyst (vitrified-warmed) | 1 | 33.3 | 0 | 0 | – |
| 1 | Blastocyst (vitrified-warmed) | 0 | – | – | ||||||||||||||||
| 1 | Blastocyst (vitrified-warmed) | 0 | – | – | ||||||||||||||||
| 9 | ALL | 35 | 10 | 41 | 80 | 10 | 9 | 90.0 | 3 | 33.3 | 3(3: blastocysts) | 100 | 1 | 1 | Blastocyst (vitrified-warmed) | 1 | 100 | 1 | 100 | 1 surplus embryos were vitrified |
| 10 | T-LBL | 35 | 10 | 42 | 87 | 4 | 4 | 100.0 | 0 | 0.0 | – | – | – | – | – | – | – | – | – | 6 oocytes were still stored |
| 11 | AML | 31 | 1 | 36 | 65 | 1 | 0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – |
| 12 | ALL | 31 | 4 | 33 | 28 | 4 | 3 | 75.0 | 3 | 100.0 | 3(1:8-cell, 2: blastocysts) | 100 | – | – | – | – | – | – | – | Embryo transfer was not performed |
| 13 | ALL | 23 | 7 | 27 | 54 | 4 | 4 | 100.0 | 3 | 75.0 | 1(5-cell) | 33.3 | 1 | 1 | 5-cell (fresh) | 0 | 0 | – | – | 3 oocytes were still stored |
| 14 | MDS | 24 | 22 | 28 | 56 | 7 | 5 | 71.4 | 3 | 60.0 | 1 (8-cell) | 33.3 | 1 | 1 | 8-cell (fresh) | 1 | 100 | 1 | 100 | 15 oocytes were still stored |
| Total | – | 29.5 ± 1.1 | 112 | 34.4 ± 1.2 | 65.5 ± 5.0 | 88 | 75 | 85.2 | 60 | 80.0 | 28 | 46.7 | 17 | 17 | – | 9 | 52.9 | 7 | 41.2 | – |
*
CML, chronic myeloid leukaemia; NHL, non-Hodgkin’s lymphoma; AA, aplastic anaemia; ALL, acute lymphoid leukaemia; AML, acute myeloid leukaemia; T-LBL, T-cell lymphoblastic lymphoma; MDS, myelodysplastic syndromes.